Tune Therapeutics Secures $175M in Series B Funding to Advance Epigenome Editing Programs

Funding Amount:
Tune Therapeutics has completed over $175M in Series B financing to advance its epigenome editing programs124.

Investors:
The funding round was led by New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation124.

Clinical Trials:
The company is using the funds to support clinical trials for its lead program, Tune-401, a first-in-class epigenetic silencer for chronic Hepatitis B, which has begun in New Zealand and Hong Kong124.

Platform Technology:
Tune Therapeutics' TEMPO platform is designed to epigenetically silence viral HBV intDNA and cccDNA necessary for sustained HBV infection without altering human DNA124.

Future Applications:
The company aims to expand its pipeline to include treatments for other liver conditions and to explore the ability to reprogram cell identities through epigenetic editing4.

Previous Success:
Tune has demonstrated the effectiveness of its technology by repressing a specific gene in non-human primates and reducing LDL cholesterol levels, with ongoing reduction lasting almost two years after a single treatment14.

Sources:

1. https://www.biospace.com/press-releases/tune-therapeutics-completes-over-175m-in-series-b-financing-to-advance-field-leading-epigenome-editing-programs

2. https://www.axios.com/local/raleigh/2025/01/13/durham-biotech-firm-tune-therapeutics-raises-175-million

4. https://www.geekwire.com/2025/seattle-biotech-startup-tune-therapeutics-lands-175m-to-support-clinical-research/